Base editing rescue of spinal muscular atrophy in cells and in mice-Reference-Cited by-全球学者库

Base editing rescue of spinal muscular atrophy in cells and in mice

Published:2023-04-21 Issue:6642 Volume:380 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Arbab Mandana¹²³⁴^ORCID,Matuszek Zaneta³⁴⁵^ORCID,Kray Kaitlyn M.⁶^ORCID,Du Ailing⁷^ORCID,Newby Gregory A.³⁴^ORCID,Blatnik Anton J.⁶^ORCID,Raguram Aditya³⁴^ORCID,Richter Michelle F.³⁴^ORCID,Zhao Kevin T.³⁴^ORCID,Levy Jonathan M.³⁴^ORCID,Shen Max W.³⁴⁸,Arnold W. David⁹¹⁰^ORCID,Wang Dan⁷¹¹^ORCID,Xie Jun⁷^ORCID,Gao Guangping⁷¹²^ORCID,Burghes Arthur H. M.⁶^ORCID,Liu David R.³⁴¹³^ORCID

Affiliation:

1. Department of Neurology, Rosamund Stone Zander Translational Neuroscience Center, Boston Children’s Hospital, Boston, MA 02115, USA.

2. Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA.

3. Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.

4. Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.

5. Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA.

6. Department of Biological Chemistry and Pharmacology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.

7. Horae Gene Therapy Center, UMass Chan Medical School, University of Massachusetts, Worcester, MA 01605, USA.

8. Computational and Systems Biology Program, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

9. Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.

10. NextGen Precision Health, University of Missouri, Columbia, MO 65212, USA.

11. RNA Therapeutics Institute, UMass Chan Medical School, University of Massachusetts, Worcester, MA 01605, USA.

12. Microbiology and Physiological Systems, UMass Chan Medical School, University of Massachusetts, Worcester, MA 01605, USA.

13. Howard Hughes Medical Institute, Harvard University, Cambridge, MA 02138, USA.

Abstract

Spinal muscular atrophy (SMA), the leading genetic cause of infant mortality, arises from survival motor neuron (SMN) protein insufficiency resulting from SMN1 loss. Approved therapies circumvent endogenous SMN regulation and require repeated dosing or may wane. We describe genome editing of SMN2 , an insufficient copy of SMN1 harboring a C6>T mutation, to permanently restore SMN protein levels and rescue SMA phenotypes. We used nucleases or base editors to modify five SMN2 regulatory regions. Base editing converted SMN2 T6>C, restoring SMN protein levels to wild type. Adeno-associated virus serotype 9–mediated base editor delivery in Δ7SMA mice yielded 87% average T6>C conversion, improved motor function, and extended average life span, which was enhanced by one-time base editor and nusinersen coadministration (111 versus 17 days untreated). These findings demonstrate the potential of a one-time base editing treatment for SMA.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Link

https://www.science.org/doi/pdf/10.1126/science.adg6518

Reference160 articles.

1. Identification and characterization of a spinal muscular atrophy-determining gene

2. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens

3. The Genetic Component in Child Mortality

4. Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells

5. SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety Review of Therapeutic Ultrasound for Spinal Cord Neuromodulation and Blood–Spinal Cord Barrier Opening;Ultrasound in Medicine & Biology;2024-03

2. CRISPR technologies for genome, epigenome and transcriptome editing;Nature Reviews Molecular Cell Biology;2024-02-02

3. Next-generation biological vector platforms for in vivo delivery of genome editing agents;Current Opinion in Biotechnology;2024-02

4. Applications of CRISPR technologies to the development of gene and cell therapy;BMB Reports;2024-01-04

5. An adenine base editor variant expands context compatibility;Nature Biotechnology;2024-01-02